Blood tests could reveal inflammation in methamphetamine users

NCT ID NCT07450027

Recruiting now Knowledge-focused Sponsor: Elazığ Mental Health and Diseases Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study measures two blood proteins, LRFN5 and OLFM4, in people with methamphetamine use disorder, those with methamphetamine-induced psychosis, and healthy volunteers. Researchers want to see if these markers are linked to inflammation and symptom severity. The study involves 120 participants and does not test any treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help identify blood markers that indicate inflammation or severity of symptoms in methamphetamine-related disorders.
What could go wrong: This is an early observational study, not a treatment trial. It may not find clear links between the markers and the conditions, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METHAMPHETAMINE INDUCED PSYCHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

methamphetamine dependence methamphetamine-induced psychosis Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METHAMPHETAMINE INDUCED PSYCHOSIS METHAMPHETAMINE USE DISORDER

Contacts and locations

Locations

Elazığ Mental Health and Diseases Hospital
RECRUITING

Elâzığ, Elâzığ, 23200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.